(R)-tert-Butyl 1-(benzylamino)-3-methoxy-1-oxopropan-2-ylcarbamate

We are (R)-tert-Butyl 1-(benzylamino)-3-methoxy-1-oxopropan-2-ylcarbamate CAS:880468-89-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(R)-tert-Butyl 1-(benzylamino)-3-methoxy-1-oxopropan-2-ylcarbamate
CAS.NO:880468-89-3
Synonyms:(R)-tert-Butyl 1-(benzylamino)-3-methoxy-1-oxopropan-2-ylcarbamate
TERT-BUTYL N-[(1R)-1-(BENZYLCARBAMOYL)-2-METHOXYETHYL]CARBAMATE
(R)-N-benzyl-2-N-Boc-amino-3-methoxypropionamide
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 507.6±50.0 °C at 760 mmHg
Molecular Formula C16H24N2O4
Molecular Weight 308.373
Flash Point 260.8±30.1 °C
Vapour Pressure 0.0±1.3 mmHg at 25°C
Index of Refraction 1.510
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
Isomers:≤0.5%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lacosamide(CAS:175481-36-4).

(R)-tert-Butyl 1-(benzylamino)-3-methoxy-1-oxopropan-2-ylcarbamate


Related News: Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.2'-deoxyuridine CAS:951-78-0 Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.2-Chloronicotinic acid Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added “The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.761440-75-9 It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API.

Related Products
Product Name
3-Fluoro-5-nitrotoluene View Details
Palladium Nitrate Cas:10102-05-3 View Details
Side Chain For Meropenem Cas:96034-64-9 View Details
3-Bromo-2-pyridinecarboxylic acid manufacturer 3-Acetyl-2,5-dichlorothiophene manufacturer 4-amino-5-ethylsulfanyl-2-methoxybenzoic acid manufacturer Tert-buthyl Pitavastatin Cas:586966-54-3 manufacturer titanium ethylhexoxide Cas:1070-10-6 manufacturer